Mar. Drugs 2013, 11(6), 1878-1898; doi:10.3390/md11061878
Article

Subtilomycin: A New Lantibiotic from Bacillus subtilis Strain MMA7 Isolated from the Marine Sponge Haliclona simulans

1 Department of Microbiology, University College Cork, Cork, Ireland 2 Biomerit Research Centre, Department of Microbiology, University College Cork, Cork, Ireland 3 Teagasc Food Research Centre, Teagasc, Moorepark, Fermoy, Co. Cork, Ireland 4 Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland 5 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA 6 Marine Biotechnology Centre, Environmental Research Institute, University College Cork, Cork, Ireland 7 School of Pharmacy, University College Cork, Cork, Ireland
* Authors to whom correspondence should be addressed.
Received: 25 April 2013; in revised form: 13 May 2013 / Accepted: 15 May 2013 / Published: 3 June 2013
(This article belongs to the Special Issue Marine Peptides and Their Mimetics)
PDF Full-text Download PDF Full-Text [741 KB, Updated Version, uploaded 6 June 2013 15:14 CEST]
The original version is still available [757 KB, uploaded 3 June 2013 13:24 CEST]
Abstract: Bacteriocins are attracting increased attention as an alternative to classic antibiotics in the fight against infectious disease and multidrug resistant pathogens. Bacillus subtilis strain MMA7 isolated from the marine sponge Haliclona simulans displays a broad spectrum antimicrobial activity, which includes Gram-positive and Gram-negative pathogens, as well as several pathogenic Candida species. This activity is in part associated with a newly identified lantibiotic, herein named as subtilomycin. The proposed biosynthetic cluster is composed of six genes, including protein-coding genes for LanB-like dehydratase and LanC-like cyclase modification enzymes, characteristic of the class I lantibiotics. The subtilomycin biosynthetic cluster in B. subtilis strain MMA7 is found in place of the sporulation killing factor (skf) operon, reported in many B. subtilis isolates and involved in a bacterial cannibalistic behaviour intended to delay sporulation. The presence of the subtilomycin biosynthetic cluster appears to be widespread amongst B. subtilis strains isolated from different shallow and deep water marine sponges. Subtilomycin possesses several desirable industrial and pharmaceutical physicochemical properties, including activity over a wide pH range, thermal resistance and water solubility. Additionally, the production of the lantibiotic subtilomycin could be a desirable property should B. subtilis strain MMA7 be employed as a probiotic in aquaculture applications.
Keywords: antimicrobial; subtilomycin; lantibiotic; marine sponge; Bacillus subtilis

Supplementary Files

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Phelan, R.W.; Barret, M.; Cotter, P.D.; O'Connor, P.M.; Chen, R.; Morrissey, J.P.; Dobson, A.D.W.; O'Gara, F.; Barbosa, T.M. Subtilomycin: A New Lantibiotic from Bacillus subtilis Strain MMA7 Isolated from the Marine Sponge Haliclona simulans. Mar. Drugs 2013, 11, 1878-1898.

AMA Style

Phelan RW, Barret M, Cotter PD, O'Connor PM, Chen R, Morrissey JP, Dobson ADW, O'Gara F, Barbosa TM. Subtilomycin: A New Lantibiotic from Bacillus subtilis Strain MMA7 Isolated from the Marine Sponge Haliclona simulans. Marine Drugs. 2013; 11(6):1878-1898.

Chicago/Turabian Style

Phelan, Robert W.; Barret, Matthieu; Cotter, Paul D.; O'Connor, Paula M.; Chen, Rui; Morrissey, John P.; Dobson, Alan D.W.; O'Gara, Fergal; Barbosa, Teresa M. 2013. "Subtilomycin: A New Lantibiotic from Bacillus subtilis Strain MMA7 Isolated from the Marine Sponge Haliclona simulans." Mar. Drugs 11, no. 6: 1878-1898.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert